The US IPO market slowed this week with four small companies raising less than $100 million in their deals and seeing lukewarm receptions from IPO investors. Biotechs Zogenix (ZGNX) and Anacor Pharmaceuticals (ANAC) both slashed the offer prices by roughly ...read more
SYSWIN, a leading provider of real estate agency services to property developers in Beijing, raised $67 million by selling 9.6 million ADSs at $7, well below its originally anticipated terms of 12 million ADSs at a price of $9.25 to $11.25. Earlier on Tuesday, ...read more
Zogenix, which recently launched Sumavel DosePro, a needle-free injectable migraine treatment, raised $56 million by offering 14 million shares (versus 6 million shares as originally planned) at $4, a sharp 69% discount to its proposed range of $12 to $14. ...read more
The following IPOs are expected to price this week: Anacor Pharmaceuticals (ANAC), which is developing treatments for nail fungus and psoriasis using boron-based chemistry, plans to raise $80 million by offering 4.7 million shares at a price range of $16-$18. ...read more
US IPO market slows pace in shortened holiday week with four tepid debuts
The US IPO market slowed this week with four small companies raising less than $100 million in their deals and seeing lukewarm receptions from IPO investors. Biotechs Zogenix (ZGNX) and Anacor Pharmaceuticals (ANAC) both slashed the offer prices by roughly ...read more
Chinese real estate agency services provider SYSWIN prices IPO at $7 per ADS; raises $67 million
SYSWIN, a leading provider of real estate agency services to property developers in Beijing, raised $67 million by selling 9.6 million ADSs at $7, well below its originally anticipated terms of 12 million ADSs at a price of $9.25 to $11.25. Earlier on Tuesday, ...read more
Zogenix prices IPO at $4, raises $56 million to fund drug development
Zogenix, which recently launched Sumavel DosePro, a needle-free injectable migraine treatment, raised $56 million by offering 14 million shares (versus 6 million shares as originally planned) at $4, a sharp 69% discount to its proposed range of $12 to $14. ...read more
4 IPOs planned for the week of Nov 22
The following IPOs are expected to price this week: Anacor Pharmaceuticals (ANAC), which is developing treatments for nail fungus and psoriasis using boron-based chemistry, plans to raise $80 million by offering 4.7 million shares at a price range of $16-$18. ...read more